scholarly journals CIRUGÍA DE CÁNCER DE PULMÓN EN ESTADIO TEMPRANO EN LESIÓN CAVITARIA QUE SIMULABA ABSCESO PULMONAR, REPORTE DE CASO.

2021 ◽  
Vol 32 (1) ◽  
pp. s11-s12
Author(s):  
Eddyn Ruben Macias ◽  
Diana Margarita Iñahuazo ◽  
Diana Elizabeth Peñaloza ◽  
María de Lourdes Garcés
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Chest Radiography ◽  
Lower Lobe ◽  
Imaging Study ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Hepatic Function ◽  
Bronchial Tree ◽  
Improve Patient Survival

Introduction Pulmonary cavitations are defined as a space filled with air, within a pulmonary area of consolidation, a mass or a nodule, they are produced by the expulsion or drainage of the necrotic part of the lesion through the bronchial tree. The most frequent causes are infectious by mycobacteria as in tuberculosis, or bacteria as in necrotizing pneumonia, pulmonary abscesses, although on rare occasions, it can also present in pulmonary embolism with infarction. Neoplasms should always be suspected, being squamous cell carcinoma the one that has been related to a greater extent to pulmonary cavitary lesion, and to a lesser extent to adenocarcinoma. Other less frequent causes are granulomatosis with polyangiitis, lymphomas, pneumoconiosis, silicosis. Case description Patient with respiratory symptoms of one year of evolution, characterized by cough with sporadic yellowish expectoration plus chest pain, in 03/2020 is accompanied by hemoptysis and progressive dyspnea, without weight loss or fever, private physician indicates antibiotic with partial improvement; On 08/2020 she presented hemoptysis, she went to the doctor again and requested a tomographic study in which she showed evidence of pulmonary cavitation associated with consolidation, a new antibiotic scheme was administered, without improvement, and she went to this clinic on 11/2020. New tomographic study showed cavitation with thick walls, preserved renal and hepatic function, infectious profile and negative immunological tests. Bronchoscopy with BAL cytology positive for malignancy, simple and contrasted body tomography and PET SCAN were indicated, showing hypermetabolic mass in the right lower lobe, with no evidence of distant metastasis or affected lymph nodes. Pulmonary function is assessed for surgical resolution, being adequate, right lower lobectomy is performed, showing free surgical edges, with negative regional nodes for malignancy, with pathology reporting lung adenocarcinoma, pathological staging T3N0, and according to the imaging study M0, determining stage IIB. He required chemotherapy and adjuvant radiotherapy. Conclusion Lung cancer symptomatology can be silent and mainly non-specific, in the study by Bradley et al. addressing lung cancer risk by symptomatology and by chest radiography, they conclude that chest radiography has limited sensitivity and that only hemoptysis has a statistically significant predictive value for malignancy. In relation to cavitated lesions as a presentation in lung cancer, they are evidenced in 5 to 15% of all patients. Within primary neoplasms the frequency with which we can observe cavitation of the lesion is related to the histological subtype, it is more frequent in squamous carcinomas (9-38%), rarer in adenocarcinomas (6-15%) and large cell carcinoma, and practically rules out small cell carcinoma. As conclusions, multidisciplinary management allows adequate orientation in both the diagnostic and therapeutic algorithm of patients, which will improve patient survival.

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.

1985 ◽  
Vol 3 (11) ◽  
pp. 1478-1485 ◽  
Author(s):  
D Osoba ◽  
J J Rusthoven ◽  
K A Turnbull ◽  
W K Evans ◽  
F A Shepherd
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Entire Group ◽  
Small Cell Lung

Fifty-three patients with recurrent and advanced stage (III and IV) non-small-cell lung cancer (NSCLC) were treated with a combination of bleomycin, etoposide (VP-16-213), and cis-diamminedichloroplatinum (BEP). Forty-eight patients were appraisable for response. The response rates were 44% for the entire group, 57% in 30 patients with combined squamous-cell and large-cell carcinoma, and 22% in 18 patients with adenocarcinoma (40%, 50%, and 19%, respectively, if patients not appraisable for response are included as nonresponders). The median survival time of patients with squamous-cell and large-cell carcinoma was slightly longer than that of patients with adenocarcinoma (23 weeks v 19 weeks). Patients with responsive disease survived significantly longer (median, 34 weeks) than did patients with unresponsive disease (median, 16 weeks) (P = .001). In the entire group, the median survival time of patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 was better (23 weeks) than of those with a status of 2 or 3 (15 weeks), but this difference was not seen in the subgroup with squamous-cell and large-cell carcinoma (24 weeks v 23 weeks, respectively). Thus, the performance status was not of prognostic value in the histologic subgroups experiencing the best response rate. There were two treatment-related deaths, but otherwise the toxicity of BEP was acceptable. Only four of the 119 treatment cycles were followed by fever even though there was significant neutropenia (0.5 X 10(9)/L) after 20 of 97 treatment cycles. The majority of patients receiving BEP experienced relief of cough, hemoptysis, pain, and fatigue associated with their disease. There was a good correlation between objective responses and palliation of symptoms. Thus, BEP offers good palliation, particularly for patients with squamous-cell and large-cell lung cancer.

Lung Cancer - Part I

2019 ◽  
Author(s):  
Jeffrey Crawford ◽  
John Strickler
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses both NSCLC and small cell lung cancer (SCLC), including lung cancer in those who have never smoked, prevention of lung cancer, with sections on diagnosis, biomarkers, treatment, and supportive care.  This review contains 7 figures, 10 tables, and 74 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Lung Cancer - Part I

2019 ◽  
Author(s):  
Jeffrey Crawford ◽  
John Strickler
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses both NSCLC and small cell lung cancer (SCLC), including lung cancer in those who have never smoked, prevention of lung cancer, with sections on diagnosis, biomarkers, treatment, and supportive care.  This review contains 7 figures, 10 tables, and 74 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Lung Cancer Part II

2019 ◽  
Author(s):  
Jeffrey Crawford
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses treatment of both NSCLC and small cell lung cancer (SCLC). This review 2 figures, 19 tables, and 90 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Clinical Characteristics and Surgery of Primary Lung Cancer in Younger Patients

2008 ◽  
Vol 16 (5) ◽  
pp. 387-391 ◽  
Author(s):  
Yasunobu Funakoshi ◽  
Shin-Ichi Takeda ◽  
Yoshihisa Kadota ◽  
Takashi Kusu ◽  
Hajime Maeda
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Older Patients ◽  
Clinical Characteristics ◽  
Early Stage ◽  
Survival Rates ◽  
Primary Lung Cancer ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Younger Patients

Controversy exists regarding the clinical characteristics, pathological findings, and prognosis of patients < 50 years of age with primary lung cancer. The medical records of 4,556 patients diagnosed with primary lung cancer between 1980 and 2004 were reviewed; of these, 305 were < 50 years old. Of 1,335 patients who were surgically treated, 122 were < 50 years old. Females were over-represented in the younger group. Younger patients had a significantly higher incidence of adenocarcinoma and large cell carcinoma, and a lower incidence of squamous cell carcinoma. The resectable rate in younger patients was significantly higher. Overall and among surgically treated patients, the survival rates of younger patients with stage 0-I disease were significantly better than those of older patients. Younger patients with early-stage primary lung cancer had a significantly better prognosis than older patients, although survival in the advanced stages was not significantly different.

Introduction to Neoplasms of the Lung and Tracheobronchial Tree

Chest Imaging ◽  
2019 ◽  
pp. 253-255
Author(s):  
Melissa L. Rosado-de-Christenson
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Lung Neoplasm ◽  
Pulmonary Nodules ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Cell Types ◽  
Tracheobronchial Tree ◽  
Pulmonary Neoplasms ◽  
Lung Malignancy

The introduction to neoplasms of the lung and tracheobronchial tree addresses the different types of malignant and benign neoplasms of the lung. The most common primary lung neoplasm is lung cancer. It represents the most common cause of cancer mortality in American men and women. Lung cancer is comprised by four major cell types including adenocarcinoma, squamous cell carcinoma, small cell carcinoma and large cell carcinoma. Many patients with lung cancer are symptomatic at presentation and most present with advanced disease. Lung cancer has a variety of imaging manifestations including nodules, masses, post-obstructive atelectasis/pneumonia, intrathoracic lymphadenopathy, extrapulmonary involvement and/or metastatic disease. Carcinoid tumor is an uncommon primary lung malignancy that often affects the airways, but typically exhibits an indolent behavior. Benign pulmonary neoplasms are rare and include neoplasms of the lung and airways such as hamartoma and endobronchial mesenchymal neoplasms. Pulmonary metastases are probably the most common pulmonary neoplasms and usually manifest as multifocal pulmonary nodules and masses.

scholarly journals Large Cell Carcinoma Mimicking Non Resolving Pneumonia

1970 ◽  
Vol 12 (2) ◽  
pp. 166-169
Author(s):  
Mohammad Ashik Imran Khan ◽  
MD Titu Miah ◽  
MD Shahriar Mahbub ◽  
Ratan Das Gupta ◽  
HAM Nazmul Ahasan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Chest Pain ◽  
Cell Carcinoma ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Community Acquired Pneumonia ◽  
Young Lady ◽  
Common Phenomenon ◽  
Diagnostic Challenge

Fever, chest pain, cough in a young lady usually does not ring any alarm bell. We present here a case of a young lady who had typical symptoms of community acquired pneumonia who initially responded to regular antibiotics but later was investigated to have large cell carcinoma. Presentation of lung cancer as non-resolving pneumonia is not a very common phenomenon and diagnosis can present a diagnostic challenge to the clinician. Keyword: Non-resolving pneumonia, Young lady, Chest pain, fever, Large cell Carcinoma, Bangladesh. DOI: http://dx.doi.org/10.3329/jom.v12i2.8423 JOM 2011; 12(2): 166-169

EML4-ALK mutation in Austrian patients with NSCLC: A multicenter study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e19093-e19093
Author(s):  
Maximilian J. Hochmair ◽  
Ulrike Setinek ◽  
Thomas Efstathiades ◽  
Klaus Kirchbacher ◽  
Andrea Mohn-Staudner ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Fish Analysis ◽  
Surgical Specimen ◽  
Anaplastic Lymphoma ◽  
Step Procedure ◽  
Alk Positive ◽  
Dual Colour

e19093 Background: EML4 (echinoderm microtubule-associated protein-like 4) - ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase, an oncoprotein found in a subgroup of non-small-cell lung cancer (NSCLC) predicts the response to ALK inhibitors. In general, AML4-ALK mutation is found in 2 to 7% of Caucasian patients with NSCLC and occurs more often in never and former smokers, adenocarcinomas, and younger, male patients. However, the frequency of EML4-ALK mutation in Austrian patients with NSCLC is unknown. The aim of the study was to evaluate the prevalence of EML4-ALK mutation in Austrian patients with NSCLC. Methods: From September 2011 to October 2012 tumour tissue from bronchoscopy, CT- and ultrasound guided biopsies and surgical specimen with histological type of adenocarcinoma and NSCLC NOS (Not Otherwise Specified) excluding squamous cell carcinoma, large cell carcinoma and neuroendocrine carcinoma were analysed for EML4-ALK mutations from 4 hospitals in Austria with high expertise in the management of lung cancer. Mutation detection was performed with a two-step procedure. First an immunhistochemical staining was done (ALK confirm/Ventana) and further on positive cases were tested by ALK FISH (dual colour breakapart FISH/Abbott Vysis). Results: In total 639 patients were analysed. EML4-ALK positive immunohistochemical staining was found in 35 patients (5,48%). 14 of these patients (2,19%) showed positive ALK FISH analysis. Conclusions: Frequency of EML-ALK mutations in Austrian patients with NSCLC was similar to other Caucasian peers.

scholarly journals Is carrot consumption associated with a decreased risk of lung cancer? A meta-analysis of observational studies

2019 ◽  
Vol 122 (5) ◽  
pp. 488-498 ◽  
Author(s):  
Hongbin Xu ◽  
Heng Jiang ◽  
Wei Yang ◽  
Fujian Song ◽  
Shijiao Yan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Prospective Cohort ◽  
Observational Studies ◽  
Meta Analysis ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Case Control ◽  
Case Control Studies ◽  
Epidemiological Evidence

AbstractFindings of epidemiological studies regarding the association between carrot consumption and lung cancer risk remain inconsistent. The present study aimed to summarise the current epidemiological evidence concerning carrot intake and lung cancer risk with a meta-analysis. We conducted a meta-analysis of case–control and prospective cohort studies, and searched PubMed and Embase databases from their inception to April 2018 without restriction by language. We also reviewed reference lists from included articles. Prospective cohort or case–control studies reporting OR or relative risk with the corresponding 95 % CI of the risk lung cancer for the highest compared with the lowest category of carrot intake. A total of eighteen eligible studies (seventeen case–control studies and one prospective cohort study) were included, involving 202 969 individuals and 5517 patients with lung cancer. The pooled OR of eighteen studies for lung cancer was 0·58 (95 % CI 0·45, 0·74) by comparing the highest category with the lowest category of carrot consumption. Based on subgroup analyses for the types of lung cancer, we pooled that squamous cell carcinoma (OR 0·52, 95 % CI 0·19, 1·45), small-cell carcinoma (OR 0·43, 95 % CI 0·12, 1·59), adenocarcinoma (OR 0·34, 95 % CI 0·15, 0·79), large-cell carcinoma (OR 0·40, 95 % CI 0·10, 1·57), squamous and small-cell carcinoma (OR 0·85, 95 % CI 0·45, 1·62), adenocarcinoma and large-cell carcinoma (OR 0·20, 95 % CI 0·02, 1·70) and mixed types (OR 0·61, 95 % CI 0·46, 0·81). Exclusion of any single study did not materially alter the pooled OR. Integrated epidemiological evidence from observational studies supported the hypothesis that carrot consumption may decrease the risk of lung cancer, especially for adenocarcinoma.

Lobectomy with Bronchoplastic Procedures for Lung Cancer

1979 ◽  
Vol 65 (5) ◽  
pp. 643-648 ◽  
Author(s):  
Maurizio Valente ◽  
Cesare Grandi ◽  
Ignazio Cataldo ◽  
Giorgio Pizzocaro ◽  
Gianni Ravasi
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Carcinoma ◽  
Large Cell Carcinoma ◽  
Distant Metastases ◽  
Large Cell ◽  
Sleeve Lobectomy ◽  
Surgical Specimen ◽  
Bronchoplastic Procedures ◽  
Oat Cell Carcinoma

From April 1970 to October 1977, 19 patients with lung cancer of the upper lobar bronchus orifice underwent radical lobectomy with major bronchus resection. Sleeve lobectomy was accomplished in 11 cases and wedge lobectomy in the remaining 8. The length of the free bronchial margin in the surgical specimen was less than 1 cm in 3 cases, but limited pulmonary reserve did not allow pneumonectomy. Squamous carcinoma was diagnosed in 14 patients, adenocarcinoma in 2, oat-cell carcinoma in 2, and large cell carcinoma in one. Most cases (70%) were pathological stage I. There was one operative death due to anastomotic leakage (5%), and another patient required pneumonectomy completion. Of 13 patients with non oat-cell carcinoma and adequate bronchial resection, none had local recurrence: 3 patients developed distant metastases, and 10 are alive and disease-free after a follow-up period ranging from 16 to 104 months. The authors conclude that in selected lung cancer patients lobectomy with bronchoplastic procedures is superior to pneumonectomy for tissue sparing advantages.

Sign in / Sign up

Export Citation Format

Share Document